Home | Publications | Drug Delivery place holder
place holder place holder

Drug Delivery

Insulin Delivery Systems Market Analysis (2007-2010)


Publication Date   May 2007
Publisher   RNCOS
Product Type   Strategic Report
Pages   105
ISBN Number   not applicable
Product Code   RCS285
Ask a question about this product?

Price £695.00

approximately: $1,376 | €883

Summary


The report "Insulin Delivery Systems Market Analysis (2007-2010)" provides an updated view on the global Insulin delivery industry, examining and giving a detailed analysis of the various devices used for Insulin delivery. It examines the key trends that are governing the market at present and where the insulin market will head in the future. The report also covers a complete analysis of the insulin markets in the countries having the maximum number of diabetic population.

Key Findings

  • The total number of diabetes patients in the world is expected to grow from 246 Million in 2006 to 380 Million by 2025.
  • Growing at a CAGR of 14.09%, global insulin market will reach US$ 14.5 Billion by 2010 from US$ 7.5 Billion in 2005.
  • Over 60% of the insulin sold in 2006 was sold in pen devices.
  • Insulin pen devices dominate the market in Europe and Japan whereas syringes and pumps dominate the US market.
  • Needle-free injectors haven't created any impact in the insulin delivery market with market share in 2006 as low as 0.6% in US.
  • Inhaled Insulin devices were earlier thought to make a big success, but Pfizer's Exubera was a big flop in 2006 with estimated revenues of 1/10th as what had been earlier projected.
  • The Insulin market in 2006 was largely dominated by two players, Novo Nordisk of Denmark and Eli Lilly of USA.
  • India and China are emerging as the most potential future markets for insulin delivery devices.

Key Issues and Facts Analyzed

The market research report also addresses the issues and facts that are critical to your business success:

  • Evaluation of past, current and future market trends.
  • Discussion about the modes of insulin delivery.
  • A detailed analysis of the major insulin delivery devices.
  • Analysis of pros and cons of major insulin devices.
  • Scope of the major insulin delivery systems all over the world.
  • Analysis of various challenges and opportunities for the industry.
  • Profile discussion of key players in the sector.

Key Players Analyzed

This section provides the overview, key facts, and financial information of prominent players in the global insulin delivery market like Eli Lilly & Company, Novo Nordisk A/S, Sanofi-Aventis, GlaxoSmithKline, and Amylin Pharmaceuticals, Inc.

Research Methodology Used

Information Sources

Information has been sourced from various sources like books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to access to more than 3000 paid databases.

Analysis Methods

The analysis methods includes the following:

Ratio Analysis, Historical Trend Analysis, Linear Regression Analysis using software tools, Judgmental Forecasting, and Cause and Effect Analysis.

Content


  • 1. Analyst View
  • 2. Research Overview
  • 3. Diabetes Disease Indicator
  • 4. Diabetes & Obesity
  • 5. Global Market Analysis
    • 5.1 Global Diabetes Drugs Market
    • 5.2 Global Insulin Market
      • 5.2.1 India
        • 5.2.1.1 Prevalence
        • 5.2.1.2 Market Analysis
      • 5.2.2 China
        • 5.2.2.1 Prevalence
        • 5.2.2.2 Market Analysis
      • 5.2.3 US
        • 5.2.3.1 Prevalence
        • 5.2.3.2 Market Analysis
      • 5.2.4 Russia
        • 5.2.4.1 Prevalence
        • 5.2.4.2 Market Analysis
      • 5.2.5 Japan
        • 5.2.5.1 Prevalence
        • 5.2.5.2 Market Analysis
      • 5.2.6 Germany
        • 5.2.6.1 Prevalence
        • 5.2.6.2 Market Analysis
      • 5.2.7 Pakistan
        • 5.2.7.1 Prevalence
        • 5.2.7.2 Market Analysis
      • 5.2.8 Brazil
        • 5.2.8.1 Prevalence
        • 5.2.8.2 Market Analysis
      • 5.2.9 Mexico
        • 5.2.9.1 Prevalence
      • 5.2.10 Egypt
        • 5.2.10.1 Prevalence
  • 6. Insulin Delivery Devices
    • 6.1 Present Devices
      • 6.1.1 Insulin Syringes
        • 6.1.1.1 Mechanism & Technology
        • 6.1.1.2 Market Analysis
        • 6.1.1.3 Pros & Cons
        • 6.1.1.4 Future Outlook (2007-2010)
        • 6.1.1.5 Key Players in Insulin Syringe Market
      • 6.1.2 Insulin Pen Devices
        • 6.1.2.1 Mechanism & Technologies
        • 6.1.2.2 Market Analysis
        • 6.1.2.3 Pros & Cons
        • 6.1.2.4 Future Outlook (2007-2010)
        • 6.1.2.5 Key Players in Pen Devices Market
      • 6.1.3 Insulin Jet Injectors
        • 6.1.3.1 Mechanism & Technologies
        • 6.1.3.2 Market Analysis
        • 6.1.3.3 Pros & Cons
        • 6.1.3.4 Future Outlook (2007-2010)
        • 6.1.3.5 Key Players in Insulin Jet Injector Market
      • 6.1.4 Insulin Pumps
        • 6.1.4.1 Mechanism & Technologies
        • 6.1.4.2 Market Analysis
        • 6.1.4.3 Pros & Cons
        • 6.1.4.4 Future Outlook (2007-2010)
        • 6.1.4.5 Key Players in Insulin Pump Market
    • 6.2 Future Devices
      • 6.2.1 Inhaled Insulin Devices
        • 6.2.1.1 Mechanism & Technologies
        • 6.2.1.2 Market Analysis
        • 6.2.1.3 Pros & Cons
        • 6.2.1.4 Key Players in Inhaled Insulin Market
      • 6.2.2 Other Future Devices
        • 6.2.2.1 Oral Insulin
        • 6.2.2.2 Insulin Patch
        • 6.2.2.3 Implantable Insulin Pump
  • 7. Industry Analysis
    • 7.1 Drivers
      • 7.1.1 Increasing Number of Diabetic Patients
      • 7.1.2 Convenient & Less Painful Modes of Insulin Delivery
      • 7.1.3 Improved Access & Lower Insulin Prices in the Developing World
      • 7.1.4 Early Diagnosis & Increasing Awareness for Treatment
      • 7.1.5 Government Support
    • 7.2 Challenges
      • 7.2.1 High R&D & Production Cost
      • 7.2.2 Long Time to Market
      • 7.2.3 Poverty
      • 7.2.4 Insurance Reimbursement
      • 7.2.5 Traditional Treatments
      • 7.2.6 High Cost of Insulin Inhalers
      • 7.2.7 Rapidly Changing Technology
    • 7.3 Opportunities
      • 7.3.1 US & Developing Countries - Potential Markets for Insulin Syringes
      • 7.3.2 Europe & Japan - Potential Markets for Pen Devices
      • 7.3.3 Oral Insulin for the Developed World
      • 7.3.4 US - Increased Insulin Pumps Sales in Future
    • 7.4 Future Outlook, 2025
      • 7.4.1 Overview of Global Diabetes Drug Market (2007-2012)
  • 8. Key Players
    • 8.1 Eli Lilly & Company
    • 8.2 Novo Nordisk A/S
    • 8.3 Sanofi-Aventis
    • 8.4 GlaxoSmithKline
    • 8.5 Amylin Pharmaceuticals, Inc
  • List of Figures:
    • Figure 4-1: Worldwide - Overweight & Obese Population of Age above 15 years (in Billion), 2005, 2007E & 2015E
    • Figure 5-1: Worldwide - Number of Diabetes Patients (in Million), 2005 & 2006
    • Figure 5-2: Worldwide - Diabetes Drug Market (in Billion US$), 2005 & 2006
    • Figure 5-3: Worldwide - Insulin Market (in Billion US$), 2005 & 2006
    • Figure 5-4: India - Number of Diagnosed Diabetes Patients (in '000), 2003-2006E
    • Figure 5-5: India - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
    • Figure 5-6: India - Insulin Market (in Million US$), 2004-2007E
    • Figure 5-7: India - Insulin Market Share of Players (%), 2004
    • Figure 5-8: China - Number of Diagnosed Diabetes Patients (in '000), 2003-2006E
    • Figure 5-9: China - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
    • Figure 5-10: China - Insulin Market (in Million US$), 2006-2009E
    • Figure 5-11: China - Insulin Market Share by Players (%), 2005
    • Figure 5-12: US - Number of Diagnosed Diabetes Patients (in '000), 2003-2006E
    • Figure 5-13: US - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
    • Figure 5-14: US - Insulin Market (in Billion US$), 2003-2006E
    • Figure 5-15: US - Insulin Market Share by Players (%), 2005
    • Figure 5-16: Russia - Number of Diagnosed Diabetes Patients (in '000), 2003-2006E
    • Figure 5-17: Russia - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
    • Figure 5-18: Russia - Insulin Market (in Million US$), 2005-2008E
    • Figure 5-19: Russia - Insulin Market Share of Players (%), 2005
    • Figure 5-20: Russia - Insulin Market by Sales Channels (%), 2005
    • Figure 5-21: Japan - Number of Diagnosed Diabetes Patients (in '000), 2003-2006E
    • Figure 5-22: Japan - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
    • Figure 5-23: Japan - Insulin Market (in Million US$), 2005-2008E
    • Figure 5-24: Japan - Insulin Market Share of Players (%), 2006
    • Figure 5-25: Germany - Number of Diagnosed Diabetes Patients (in '000), 2003-2006E
    • Figure 5-26: Germany - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
    • Figure 5-27: Germany - Insulin Market (in Billion US$), 2004-2007E
    • Figure 5-28: Pakistan - Number of Diagnosed Diabetes Patients (in '000), 2003-2006E
    • Figure 5-29: Pakistan - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
    • Figure 5-30: Brazil - Number of Diagnosed Diabetes Patients (in '000), 2003-2006E
    • Figure 5-31: Brazil - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
    • Figure 5-32: Brazil - Insulin Market (in Million US$), 2000, 2003, 2007E & 2010E
    • Figure 5-33: Mexico - Number of Diagnosed Diabetes Patients (in '000), 2003-2006E
    • Figure 5-34: Mexico - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
    • Figure 5-35: Egypt - Number of Diagnosed Diabetes Patients (in '000), 2003-2006E
    • Figure 5-36: Egypt - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
    • Figure 6-1: US - Insulin Syringes Market (in Million US$), 2003-2006E
    • Figure 6-2: US - Market Share of Insulin Syringes (%), 2003-2006E
    • Figure 6-3: US - Forecast for Insulin Syringes Market (in Million US$), 2007-2010
    • Figure 6-4: US - Forecast for Market Share of Insulin Syringes (%), 2007-2010
    • Figure 6-5: US, Europe & Japan - Percentage of Insulin Users using Pen Devices (2003-2006E)
    • Figure 6-6: US - Insulin Pen Devices Market (in Million US$), 2003-2006E
    • Figure 6-7: Worldwide - Insulin Pen Market Shares of Key Players (%), 2006
    • Figure 6-8: US - Forecast for Pen Devices Market (in Million US$), 2007-2010
    • Figure 6-9: US - Forecast for Market Share of Insulin Pen (%), 2007-2010
    • Figure 6-10: Worldwide - Jet Injectors Market (in Million US$), 2003-2006E
    • Figure 6-11: US - Insulin driven Jet Injectors Market (in Million US$), 2003-2006E
    • Figure 6-12: US - Market Share of Insulin driven Jet Injectors (%), 2003-2006E
    • Figure 6-13: Worldwide - Forecast for Insulin Delivery Jet Injectors Market (in Million US$), 2007-2010
    • Figure 6-14: US - Forecast for Insulin Delivery Jet Injectors Market (in Million US$), 2007-2010
    • Figure 6-15: US - Forecast for Market Share of Insulin Driven Jet Injectors (%), 2007-2010
    • Figure 6-16: Worldwide - Insulin Pump Market (in Billion US$), 2005 & 2006E
    • Figure 6-17: US - Insulin Pump Market (in Million US$), 2003-2006E
    • Figure 6-18: Worldwide - Forecast for Insulin Pump Market (in Million US$), 2007-2010
    • Figure 6-19: US - Forecast for Insulin Pump Market (in Million US$), 2007 & 2008
    • Figure 6-20: Worldwide - Forecast for Market Share of Inhaled Insulin Devices (%), 2015
    • Figure 7-1: Worldwide - Forecast for Number of Diabetes Patients (in Million), 2007, 2013, 2019, 2025
    • Figure 7-2: Worldwide - Forecast for Diabetes Drug Market (in Billion US$), 2007-2012
    • Figure 7-3: Worldwide - Forecast for Insulin Market (in Billion US$), 2007-2010
    • Figure 7-4: Worldwide - Forecast for Insulin Demand (in Kg), 2006-2010
  • List of Tables:
    • Table 3-1: Worldwide - Top 10 Countries with Maximum Diabetic Population in Age Group 20-79 (in Million) 2003 & 2025E
    • Table 4-1: Worldwide - Percentage of Overweight Population (2006) & Diabetic Population by Leading Countries (2003)
    • Table 5-1: List of Top 10 Anti-diabetic Brands, 2005
    • Table 5-2: India - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 5-3: India - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 5-4: China - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 5-5: China - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 5-6: US - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 5-7: US - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 5-8: Russia - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 5-9: Russia - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 5-10: Japan - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 5-11: Japan - Forecast for Diabetic Patients in 20-79 Age Group (in '000), 2025
    • Table 5-12: Germany - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 5-13: Germany - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 5-14: Pakistan - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 5-15: Pakistan - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 5-16: Brazil - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 5-17: Brazil - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 5-18: Mexico - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 5-19: Mexico - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 5-20: Egypt - Diabetic Patients in Age Group 20-79 (in '000), 2003
    • Table 5-21: Egypt - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
    • Table 8-1: Eli Lilly & Company - Key Financials (in Million US$), 2004-2006
    • Table 8-2: Novo Nordisk A/S - Key Financials (in Million US$), 2004-2006
    • Table 8-3: Sanofi-Aventis - Key Financials (in Million US$), 2003-2005
    • Table 8-4: GlaxoSmithKline - Key Financials (in Million US$), 2004-2006
    • Table 8-5: Amylin Pharmaceuticals, Inc. - Key Financials (in Million US$), 2004-2006